Literature DB >> 19959139

History of surgery for atrial fibrillation.

Zachary J Edgerton1, James R Edgerton.   

Abstract

There is a rich history of surgery for atrial fibrillation. Initial procedures were aimed at controlling the ventricular response rate. Later procedures were directed at converting atrial fibrillation to normal sinus rhythm. These culminated in the Cox Maze III procedure. While highly effective, the complexity and morbidity of the cut and sew Maze III limited its adoption. Enabling technology has developed alternate energy sources designed to produce a transmural atrial scar without cutting and sewing. Termed the Maze IV, this lessened the morbidity of the procedure and widened the applicability. Further advances in minimal access techniques are now being developed to allow totally thorascopic placement of all the left atrial lesions on the full, beating heart, using alternate energy sources.

Entities:  

Mesh:

Year:  2009        PMID: 19959139     DOI: 10.1016/j.hrthm.2009.07.047

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  4 in total

1.  A review of current surgical treatment of patients with atrial fibrillation.

Authors:  Zachary J Edgerton; James R Edgerton
Journal:  Proc (Bayl Univ Med Cent)       Date:  2012-07

2.  Surgical treatment of atrial fibrillation-what have we learned?

Authors:  John M Stulak
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

Review 3.  The Cox-maze IV procedure in its second decade: still the gold standard?

Authors:  Chawannuch Ruaengsri; Matthew R Schill; Ali J Khiabani; Richard B Schuessler; Spencer J Melby; Ralph J Damiano
Journal:  Eur J Cardiothorac Surg       Date:  2018-04-01       Impact factor: 4.191

4.  Right minithoracotomy versus conventional median sternotomy for patients undergoing mitral valve surgery and Cox-maze IV ablation with entirely bipolar radiofrequency clamp.

Authors:  Zhaolei Jiang; Min Tang; Nan Ma; Hao Liu; Fangbao Ding; Chunrong Bao; Ju Mei
Journal:  Heart Vessels       Date:  2018-02-02       Impact factor: 2.037

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.